Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B

Suparna Mazumder1, Gaurav S Choudhary, Sayer Al-Harbi

  • 1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Ohio 44195, USA.

Cancer Research
|April 25, 2012
PubMed

Insights

Resistance to ABT-737 in leukemia involves increased Mcl-1. Targeting Mcl-1 with gossypol or obatoclax can overcome this resistance, with NOXA being crucial for gossypol

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • ABT-737, a Bcl-2 homology (BH)-3 domain mimetic, targets Bcl-2 and Bcl-xL proteins.
  • Understanding resistance mechanisms to ABT-737 is crucial for leukemia treatment.

Purpose of the Study:

  • Investigate mechanisms of acquired resistance to ABT-737 in leukemia cell lines.
  • Evaluate Mcl-1 targeting agents (obatoclax, gossypol) for overcoming ABT-737 resistance.

Main Methods:

  • Developed ABT-737-resistant leukemia cell lines.
  • Analyzed Mcl-1 expression and posttranslational modifications.
  • Assessed responses to obatoclax and gossypol, including NOXA and Bim interactions.

Main Results:

  • Resistant cells exhibited increased Mcl-1 stabilization and interaction with Bim.
  • Gossypol specifically sensitized resistant cells, dependent on NOXA induction.
  • Obatoclax induced cell death in both parental and resistant cells.

Conclusions:

  • NOXA and Mcl-1 are key mediators of gossypol-induced cell death in ABT-737-resistant leukemia.
  • Targeting Mcl-1 offers a strategy to overcome ABT-737 resistance.
  • Findings provide novel insights into acquired resistance mechanisms to BH-3 mimetics.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...